Transforming Growth Factor beta1
"Transforming Growth Factor beta1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME.
| Descriptor ID |
D053773
|
| MeSH Number(s) |
D12.644.276.374.687.100 D12.644.276.954.775.100 D12.776.467.374.687.100 D12.776.467.942.775.100 D23.529.374.687.100 D23.529.942.775.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Transforming Growth Factor beta1".
Below are MeSH descriptors whose meaning is more specific than "Transforming Growth Factor beta1".
This graph shows the total number of publications written about "Transforming Growth Factor beta1" by people in this website by year, and whether "Transforming Growth Factor beta1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 6 | 6 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 6 | 6 |
| 2006 | 0 | 3 | 3 |
| 2007 | 4 | 3 | 7 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 3 | 0 | 3 |
| 2011 | 2 | 1 | 3 |
| 2012 | 3 | 3 | 6 |
| 2013 | 8 | 6 | 14 |
| 2014 | 1 | 3 | 4 |
| 2015 | 3 | 1 | 4 |
| 2016 | 1 | 2 | 3 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 3 | 4 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Transforming Growth Factor beta1" by people in Profiles.
-
Effects of emodin, a plant-derived anthraquinone, on TGF-?1-induced cardiac fibroblast activation and function. J Cell Physiol. 2021 11; 236(11):7440-7449.
-
CD70 Activation Decreases Pulmonary Fibroblast Production of Extracellular Matrix Proteins. Am J Respir Cell Mol Biol. 2020 08; 63(2):255-265.
-
Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation. Theranostics. 2020; 10(18):8365-8381.
-
Endothelial-specific deletion of Ets-1 attenuates Angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition. BMB Rep. 2019 Oct; 52(10):595-600.
-
Cutting Edge: Targeting Thrombocytes to Rewire Anticancer Immunity in the Tumor Microenvironment and Potentiate Efficacy of PD-1 Blockade. J Immunol. 2019 09 01; 203(5):1105-1110.
-
Intracellular Heat Shock Protein 70 Deficiency in Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2019 06; 60(6):629-636.
-
Effects of the isothiocyanate sulforaphane on TGF-?1-induced rat cardiac fibroblast activation and extracellular matrix interactions. J Cell Physiol. 2019 08; 234(8):13931-13941.
-
Simvastatin reduces TGF-?1-induced SMAD2/3-dependent human ventricular fibroblasts differentiation: Role of protein phosphatase activation. Int J Cardiol. 2018 Nov 01; 270:228-236.
-
TGF-?1 Suppresses IL-33-Induced Mast Cell Function. J Immunol. 2017 08 01; 199(3):866-873.
-
Sirtuin 3 Deregulation Promotes Pulmonary Fibrosis. J Gerontol A Biol Sci Med Sci. 2017 May 01; 72(5):595-602.